Recordati sees continued double-digit growth in first 9 months of 2024

8 November 2024

Italian pharma major Recordati (RECI: MI) saw its shares dip 3.75% to 50.10 euros this morning, despite posting a set of strong financial results.

Consolidated net revenue for the first nine months of 2024 was 1,743.1 million euros ($1.88 billion), up 12.0% versus the first nine months of 2023 or 9.3% on a like-for-like basis at constant exchange rates (CER). This was driven by strong business momentum across both specialty & primary care and rare diseases. T

Adjusted net income of 445.4 million euros rose9.5%. Net income of 338.4 million euros increased 11.1%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical